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FeBACKGROUND Transthyretin amyloidosis (ATTR) is a heterogeneous disorder with multiorgan involvement and a
genetic or nongenetic basis.
OBJECTIVES The goal of this study was to describe ATTR in the United States by using data from the THAOS
(Transthyretin Amyloidosis Outcomes Survey) registry.
METHODS Demographic, clinical, and genetic features of patients enrolled in the THAOS registry in the United States
(n ¼ 390) were compared with data from patients from other regions of the world (ROW) (n ¼ 2,140). The focus was on
the phenotypic expression and survival in the majority of U.S. subjects with valine-to-isoleucine substitution at position
122 (Val122Ile) (n ¼ 91) and wild-type ATTR (n ¼ 189).
RESULTS U.S. subjects are older (70 vs. 46 years), more often male (85.4% vs. 50.6%), and more often of African
descent (25.4% vs. 0.5%) than the ROW. A significantly higher percentage of U.S. patients with ATTR amyloid seen at
cardiology sites had wild-type disease than the ROW (50.5% vs. 26.2%). In the United States, 34 different mutations (n¼
201) have been reported, with the most common being Val122Ile (n ¼ 91; 45.3%) and Thr60Ala (n ¼ 41; 20.4%). Overall,
91 (85%) of 107 patients with Val122Ile were from the United States, where Val122Ile subjects were younger and more
often female and black than patients with wild-type disease, and had similar cardiac phenotype but a greater burden of
neurologic symptoms (pain, numbness, tingling, and walking disability) and worse quality of life. Advancing age and
lower mean arterial pressure, but not the presence of a transthyretin mutation, were independently associated with
higher mortality from a multivariate analysis of survival.
CONCLUSIONS In the THAOS registry, ATTR in the United States is overwhelmingly a disorder of older adult male
subjects with a cardiac-predominant phenotype. Val122Ile is the most common transthyretin mutation, and neurologic
phenotypic expression differs between wild-type disease and Val122Ile, but survival from enrollment in THAOS does not.
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BMI = body mass index
EDV = end-diastolic volume
HFpEF = heart failure in the
setting of a preserved ejection
fraction
LV = left ventricular
LVEDD = left ventricular end-
diastolic dimension
mBMI = modified body mass
index
MCF = myocardial contraction
fraction
mt-ATTR = mutated or
hereditary transthyretin
amyloidosis
QOL = quality of life
ROW = other regions of the
world
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162T ransthyretin amyloidosis (ATTR)belongs to a group of severe sys-temic conditions caused by the
extracellular deposition of insoluble protein
fibrils within tissues and organs (1). Amyloid
formation in ATTR is thought to occur when
dissociated transthyretin (TTR) monomers
misfold and assemble into amyloid fibrils,
with amyloidogenic mutation in the TTR
gene facilitating the dissociation of the
tetramer into monomers (2). Approximately
100 disease-causing TTR gene mutations (3)
have been reported; some are believed to
be associated with particular phenotypes,
although considerable variability exists
among patients (4).SEE PAGE 173There are 2 distinct types of ATTR: he-
reditary or mutated (mt-ATTR) and wild-type
(wt-ATTR; also referred to as senile systemic
amyloidosis, age-related amyloidosis, or se-
nile cardiac amyloidosis). Mt-ATTR is a rare
autosomal dominant condition caused by
mutations in the TTR gene with considerable
heterogeneity in disease presentation (5);
phenotypes can be predominantly neuro-
pathic (known as familial amyloid poly-
neuropathy) (6), predominantly cardiac (or
transthyretin cardiomyopathy [TTR-CM]),or mixed (7). The present article describes ATTR
in the United States compared with other regions
of the world (ROW). We used data from the
global THAOS (Transthyretin Amyloidosis Outcomesed from the THAOS registry, which is sponsored by Pfizer Inc. Dr
ticals, which was acquired by Pfizer in October 2010; has served o
m Pfizer for scientific meeting expenses (travel, accommodation
ard of THAOS. Dr. Damy has received grants and consulting fee
Celgene, Millennium, Pfizer, and Janssen; she has also received f
s served as a site Principal Investigator for transthyretin trials for
search funding from Pfizer. Dr. Judge has served as an advisor to
pport from and served on advisory boards for Pfizer; and current
has received support from FoldRx Pharmaceuticals as a clinical
has received grant support from Pfizer; has served on the scientifi
c meeting expenses (travel, accommodation, and registration). D
ticals as a clinical investigator and serves on the THAOS scientific
ement. Dr. Rapezzi received research grants and consultant and s
fees from Alnylam. Dr. Silver is a speaker for Amgen and serves o
pport as a clinical investigator financed by Pfizer and Alnylam; his
g in educational activities financed by Pfizer. Dr. Waddington Cru
estigator and has served on the scientific advisory board of Pfize
Mundayat is an employee of and holds stock options in Pfizer.
clinical trial. All other authors have reported that they have no r
received August 14, 2015; revised manuscript received March 23Survey) patient registry and specifically focused on
differences between the phenotypic expression and
outcomes in the majority of U.S. subjects with a
valine-to-isoleucine substitution at position 122
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METHODS
THAOS is an ongoing, global, multicenter, longitu-
dinal, observational survey open to all subjects with
ATTR (familial and wild-type) and individuals with
TTR gene mutations without a diagnosis of ATTR
(asymptomatic). The registry collects data on the
natural history of ATTR, and its principal aims are
to better understand and characterize the natural
history of the disease by studying a large, hetero-
geneous patient population. The data extracted for
this study included information on patients from 17
countries. Demographic, clinical, and genetic char-
acteristics of subjects enrolled in the THAOS regis-
try in the United States (n ¼ 390) were compared
with those observed in the ROW (n ¼ 2,140). The
design and methods of the THAOS registry,
including data collection methods and assessments,
have been previously described (8). THAOS data are
stored in a secure server maintained by Pfizer Inc.
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according to country-specific regulations and
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Although the largest number of subjects enrolled in the THAOS (Transthyretin Amyloid
Outcome Survey) registry was from Portugal, 15.4% came from the United States.
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163enrolled. All participants provide written informed
consent.
Use of THAOS data for this study was approved by
the THAOS scientific board. We included all patients
participating in the THAOS registry as of January 2015.
MEASURES. The THAOS medical history includes a
list of 75 clinical signs and symptoms that are assessed
as present or absent; if present, they are categorized
as definitely, possibly, or not related to ATTR disease.
Symptom reports collected at the time of enrollment
in THAOS were used for the present study, and
symptoms regarded by the investigator as possible or
definitely related to ATTR constituted the symptom-
atic cohort. New York Heart Association functional
class was assessed by the study team caring for the
participant according to standard definitions, and
the Norfolk Quality of Life Questionnaire–Diabetic
Neuropathy, a reliable and valid measure for identi-
fying and quantifying neuropathy and its impact on
quality of life (QOL), was administered to participants
(9). Signs and symptoms reported for at least 5% of the
patients and relevant to ATTR disease were compared
between subjects with Val122Ile and wild-type
disease, grouped according to organ system.
Data included height, weight, body mass index
(BMI), vital signs, and the Karnofsky index (10), a
clinician-rated item with scores ranging from 0 (dead)
to 100 (normal functioning; no disease) in 10-point
increments to indicate functional impairment. Ortho-
static hypotension was defined by a decline in systolic
blood pressure >20 mm Hg or a diastolic blood pres-
sure decline >10 mm Hg upon standing. The presence
or absence of a specific TTR gene mutation along with
heterozygous/homozygous state was noted.
For every tissue sample biopsied, we recorded the
source of the biopsy (e.g., fat pad, cardiac, upper or
lower gastrointestinal tract, nerve), whether amyloid
was found, if the precursor protein was evaluated for
and which technique was used (e.g., immunohisto-
chemistry, mass spectroscopy), and if TTR was
present.
Other information recorded included complete
blood cell count, clinical chemistry including the
Chem-20 screen, pre-albumin (TTR), B-type natri-
uretic peptide, N-terminal pro–B-type natriuretic
peptide, troponins T and I, and estimated glomerular
filtration rate, which were all obtained for clinical
indications. These data, along with BMI, were used to
calculate the modified BMI (mBMI), which adjusted
for malnutrition related to gastrointestinal dysfunc-
tion. The mBMI is calculated by multiplying BMI (ki-
lograms per square meter) by serum albumin
concentration (grams per liter). The mBMI, a markerof nutritional status, typically declines as the disease
progresses, especially in patients with autonomic
dysfunction, and has been shown to correlate with
survival in patients with TTR–familial amyloid poly-
neuropathy who have undergone liver trans-
plantation (11). Subjects receiving an organ transplant
and the type of organ transplanted were noted.
To quantify the impact of the ATTR on QOL, the
EuroQol-5D-3L, a standardized measure of health,
was obtained. This measure consists of 5 items used to
rate mobility, self-care, ability to perform usual ac-
tivities, pain/discomfort, and anxiety/depression on a
scale of 0 (not a problem) to 2 (unable to do/extreme
problem). In addition, a sixth item (health state) was
recorded that asked patients to rate their current
health on a visual analog scale of 0 (worst imaginable
health state) to 100 (best imaginable health state).
Twelve-lead electrocardiograms were performed
and interpreted by each site investigator. The elec-
trocardiograms included an overall interpretation as
normal/abnormal, ventricular rate, rhythm abnor-
malities (e.g., atrial fibrillation or flutter) and the
presence of low voltage or left ventricular (LV)
hypertrophy.
Echocardiographic images were obtained from the
standard parasternal long-axis/short-axis, apical, and
subcostal views. Cross-sectional, long and short axes,
apical 2-chamber, and apical 4-chamber images were
visualized. Two-dimensional measurements of the
LV end-systolic and left ventricular end-diastolic
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Noncardiologyn Values n Values n Values n Values n Values n Values
Age at registry entry, yrs 390 70  11 366 71  10 24 60  14 2,140 46  16 374 59  16 1,766 43  15 <0.0001 <0.0001 <0.0001
Male, % 390 333 (85.4) 366 318 (86.9) 24 15 (62.5) 2,140 1,082 (50.6) 374 248 (66.3) 1,766 834 (47.2) <0.0001 <0.0001 0.1366
African descent* 390 99 (25.4) 366 95 (26) 24 4 (16.7) 1,015 10 (1) 374 5 (1.3) 641 5 (0.8) <0.0001 <0.0001 <0.0001
Symptomatic† 390 330 (84.6) 366 309 (84.4) 24 21 (87.5) 2,140 1,541 (72.0) 374 290 (77.5) 1,766 1,251 (70.8) <0.0001 <0.0001 <0.0001
Asymptomatic
mutation carrier
390 20 (5.1) 366 19 (5.2) 24 1 (4.2) 2,140 577 (27.0) 374 76 (20.3) 1,766 501 (28.4) <0.0001 <0.0001 <0.0001
Type of ATTR 390 366 24 2,140 374 1,766 <0.0001 <0.0001 <0.0001
wt-ATTR 189 (48.5) 185 (50.5) 4 (16.7) 106 (5.0) 98 (26.2) 8 (0.5)































Karnofsky index (%) 182 74  15 175 74  15 7 73  5 1,946 86  15 296 83  17 1,650 87  15 <0.0001 <0.0001 0.0115
Systolic blood
pressure, mm Hg
325 115  16 305 114  16 20 121  17 2,027 124  17 352 122  17 1,675 124  17 <0.0001 <0.0001 0.3706
Diastolic blood
pressure, mm Hg
324 70  10 304 70  10 20 73  11 2,025 76  11 352 75  11 1,673 76  11 <0.0001 <0.0001 0.1221
Orthostatic hypotension 73 8 (11.0) 67 6 (9.0) 6 2 (33) 1,704 196 (11.5) 165 22 (13.3) 1,539 174 (11.3) 0.8866 0.3536 0.0901
BMI, kg/m2 312 27  5 295 27  5 17 28  5 2,040 25  9 354 26  13 1,686 24  8 <0.0001 0.1177 0.1240
Modified BMI,
kg/m2  g/dl
157 1,075  227 152 1,078  226 5 1,003  275 1,208 1,063  233 141 1,113  235 1,067 1,057  232 0.5405 0.1858 0.6061
EQ-5D health state‡ 216 68  19 212 68  19 4 45  33 1,621 73  21 260 66  23 1361 75  20 0.0003 0.3315 0.0031
Values are mean  SD, n (%), or median (10th to 90th percentile). *Excludes data from Portugal, which does not provide such information. †Symptomatic status was unknown for 40 subjects from United States and 22 subjects from other regions of the world (ROW).
‡Range: 0 to 100.

















































FIGURE 2 Distribution of Mutations
































































In the THAOS (Transthyretin Amyloid Outcome Survey) registry, variations in distribution of mutations were seen in the United States versus
other regions of the world (ROW) overall, as well as according to noncardiology or cardiology site in ROW. Val122Ile ¼ valine-to-isoleucine
substitution at position 122.
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165(LVEDD) dimensions such as interventricular septal
thickness and posterior wall thickness were obtained
according to American Society of Echocardiog-
raphy guidelines (12). Using a previously validated
technique, LV end-diastolic volume (EDV) and end-
systolic volume were calculated from reported
2-dimensional echo-guided M-mode echocardio-
graphic dimensions as follows (13): EDV ¼ 4.5 
(LVEDD)2 and end-systolic volume ¼ 3.72  (left
ventricular end-systolic)2. Using these measure-
ments, stroke volume (SV) was calculated as: EDV –
end-systolic volume. LV mass was determined by
using the formula described by Devereux et al. (14) as:
1.04  (LVEDD þ interventricular septal thickness þ
posterior wall thickness)3 – (LVEDD3) and indexed to
body surface area. Ejection fraction was calculated as:(SV/EDV)  100. Myocardial volume was defined as
LV mass divided by the mean density of myocardium
(1.04 g/ml). Myocardial contraction fraction (MCF)
was calculated as LV SV divided by LV myocardial
volume (15,16). MCF is a volumetric index of
myocardial shortening that is able to distinguish
physiologic from pathologic hypertrophy (15), predict
incident cardiovascular events (16), and is highly
correlated with global strain.
Follow-up data were obtained from the periodical,
scheduled visits (with 6-month intervals). In cases in
which no follow-up visits had been made at 1 year
from the previous visit, the investigators from the
center enrolling the patient were invited to contact
the patient (or relatives) by telephone to retrieve data
on vital status.





p Valuen Values n Values
Age at registry entry, yrs 189 76  7 91 69  10 <0.0001
Male 189 184 (97.4) 91 69 (75.8) <0.0001
Race 189 91
African descent 8 (4.2) 79 (86.8) <0.0001
White 169 (89.4) 6 (6.6)
Symptomatic* 189 166 (87.8) 91 77 (84.6) 0.3238
Duration of ATTR symptoms, yrs 163 4.9 (0.6–21.1) 75 4.2 (0.6–14.0) 0.3280
Time from ATTR
diagnosis to enrollment, yrs
140 0.37 (0.1–2.5) 60 0.36 (0.1–2.0) 0.9369
NYHA functional class 162 76
I 35 (21.6) 15 (19.7) 0.0087
II 72 (44.4) 19 (25.0)
III 51 (31.5) 37 (48.7)
IV 4 (2.5) 5 (6.6)
History of carpal tunnel syndrome 123 41 (33.3) 55 16 (29.1) 0.5751
Karnofsky index, % 84 76  13 56 70  18 0.0454
Heart rate, beats/min 154 72  12 75 80  14 <0.0001
Systolic blood pressure, mm Hg 157 115  16 77 112  17 0.1979
Diastolic blood pressure, mm Hg 156 69  10 77 69  11 0.8294
BMI, kg/m2 151 27  4 75 28  6 0.0260
Modified BMI, kg/m2  g/dl 80 1,068  199 40 1,063  211 0.9031
Norfolk QOL-DN 113 21.5  16.5 46 29.1  25.5 0.0267
EQ-5D health state† 108 69  18 49 67  19 0.4123
EQ-5D index‡
Age 50–64 yrs 8 0.94  0.1 14 0.73  0.2 0.0176
Age $65 yrs 105 0.82  0.1 32 0.75  0.2 0.0132
Values are mean  SD, n (%), or median (10th to 90th percentile). *Symptomatic status was unknown for 19
subjects with wt-ATTR and 9 subjects with valine-to-isoleucine substitution at position 122 (Val122Ile). †Range:
0 to 100. ‡Range: 0 to 1.
DN ¼ diabetic neuropathy; NYHA¼ New York Heart Association; QOL ¼ quality of life; other abbreviations as in
Table 1.
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166STATISTICAL ANALYSIS. Data are presented as mean
 SD unless otherwise noted. Differences were
assessed by using a chi-square analysis for dichoto-
mous variables and the Student t test for continuous
variables. Comparisons were made between the
United States and ROW and the 2 most common forms
of ATTR in the United States (wt-ATTR and mt-ATTR
attributable to Val122Ile) regarding demographic
characteristics, clinical features (e.g., symptoms,
electrocardiograms, echocardiogram, biomarkers),
and outcomes. To determine if mutation status
(Val122Ile vs. wild-type) was independently associ-
ated with survival, a multivariate analysis was per-
formed by using Cox proportional hazards modeling.
We also determined whether there were additional
clinical predictors of survival. Candidate predictors
considered for the multivariable model had p < 0.20
in univariate analyses. The 8 candidate predictors
(age, heart rate, estimated glomerular filtration rate,
low-voltage QRS, mean arterial pressure, SV, ejectionfraction, and MCF) were entered into a backward,
stepwise-selected model with entry/stay criteria of
p < 0.10. The 5 items of the EuroQol-5D-3L were used
to calculate the EuroQol-5D-3L index score.
RESULTS
At the time of this analysis, 22 sites (16 cardiology, 6
noncardiology) in the United States had enrolled 390
subjects, accounting for 15.4% of the total registry
population (Figure 1). Subjects in the United States
were older and were more often male subjects of
African descent (excluding data from Portugal, which
does not provide such information) than the ROW
(Table 1). A higher percentage of subjects from the
ROW were asymptomatic carriers of mutations than
in the United States. A higher percentage of subjects
with wt-ATTR were located in the United States
(Figure 2). Consistent with greater prevalence of car-
diac involvement, both systolic and diastolic blood
pressures were lower in the United States than in the
ROW, even when directly comparing cardiology sites
in the United States with ROW, and duration of dis-
ease was longer and Karnofsky index lower in the
United States. Although BMI was higher in the United
States than in the ROW, these differences did not
persist when stratified according to cardiology and
noncardiology sites, nor did the mBMI differ across
cohorts. Overall, QOL as assessed by using the EQ-5D
was poor but did not differ between the United States
and ROW among cardiology sites.
The ROW presented a greater number of distinct
mutations (Figure 2); specifically, the Val30Met mu-
tation was significantly more common in the ROW,
whereas in the United States, Val122Ile was more
common. Ninety-one (85%) of 107 patients with
Val122Ile reported were from the United States. In the
United States, 34 different mutations (n ¼ 201) have
been reported thus far in THAOS, with the most
common being Val122Ile (45.3%), Thr60Ala (20.4%),
and Val30Met (6.0%).
The type of biopsy performed differed by
geographic region. Cardiac biopsy specimens were
the predominant source of tissue obtained (64.0%) in
the United States, whereas salivary gland (42.7%) was
the most common biopsy source in the ROW. How-
ever, differences in biopsy site did not persist when
stratified according to cardiology or noncardiology
sites. To confirm that the precursor protein was TTR,
immunofluorescence was performed more commonly
in the ROW (19.2% vs. 9.6% of positive biopsy
results), and mass spectroscopy was performed more
often in the United States (37.3% vs. 1.4% of positive
biopsy results). Among symptomatic patients,





p Valuen* Values n* Values
Cardiac
Palpitation 164 20 (12.2) 75 13 (17.3) 0.2853
Rhythm disturbance 165 108 (65.5) 75 24 (32.0) <0.0001
Dizziness 164 33 (20.1) 76 16 (21.1) 0.8679
Heart failure 165 144 (87.3) 76 71 (93.4) 0.1528
Dyspnea 164 115 (70.1) 76 51 (67.1) 0.6378
Syncope 164 20 (12.2) 75 6 (8.0) 0.3338
Gait
Balance abnormality 165 10 (6.1) 73 7 (9.6) 0.3297
Walking disability 165 11 (6.7) 72 13 (18.1) 0.0075
Muscle weakness 164 16 (9.8) 74 9 (12.2) 0.5752
Gastrointestinal
Diarrhea/constipation 163 14 (8.6) 74 14 (18.9) 0.0224
Nausea 163 2 (1.2) 72 4 (5.6) 0.0525
Early satiety 163 8 (4.9) 72 3 (4.2) 0.8041
Unintentional weight loss 163 8 (4.9) 73 5 (6.8) 0.5457
Neurologic
Neuropathic pain 166 20 (12.0) 74 25 (33.8) <0.0001
Numbness 166 36 (21.7) 73 28 (38.4) 0.0073
Temperature/pain insensitivity 165 2 (1.2) 73 2 (2.7) 0.3979
Tingling 166 22 (13.3) 73 23 (31.5) 0.0009
Urinary/renal
Urinary retention 159 0 73 2 (2.7) 0.0361
Urinary incontinence 159 1 (0.6) 74 3 (4.1) 0.0610
Urinary tract infection 95 2 (2.1) 24 0 0.4735
Renal impairment 160 24 (15.0) 75 15 (20.0) 0.3369
Values are n (%). *Number of subjects with available data.
Abbreviations as in Tables 1 and 2.
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167although liver transplantation was performed less
often in the United States than in the ROW (3.3% vs.
18.6%), cardiac transplantation was more common
(3.3% vs. 1.0%) in the United States than ROW overall
(Online Table 1) but not when comparing U.S. versus
ROW cardiology sites.
Among U.S. subjects with the most common forms
of cardiac amyloidosis (wt-ATTR and Val122Ile),
those with wild-type disease were older and almost
exclusively white, whereas those with Val122Ile mu-
tations were more often of African descent. In both
wild-type and Val122Ile, a higher percentage of sub-
jects were male compared with female, but this
finding was most marked in wild-type disease.
Although the duration of disease did not differ,
subjects with Val122Ile mutations had worse New
York Heart Association functional class, faster heart
rates, and lower QOL, as indexed by EQ-5D with a
trend toward a lower Karnofsky performance
(Table 2). Cardiac symptoms, except for rhythm dis-
turbances, did not differ between wt-ATTR subjects
and those with Val122Ile mutations (Table 3); how-
ever, there was higher walking disability and more
neurologic symptoms (neuropathic pain and tingling)
in those with Val122Ile mutations than in those with
wt-ATTR.
Although low voltage on the electrocardiogram was
more common in Val122Ile subjects than in those with
wild-type disease, the majority in both groups did not
exhibit low voltage. Atrial fibrillation, conduction
disease, and placement of permanent pacemakers
were more common in subjects with wt-ATTR than in
those with Val122Ile. However, LV size, wall thick-
ness, and ejection fraction did not differ between the
Val122Ile and wild-type subjects, but B-type natri-
uretic peptide levels were higher in subjects with
Val122Ile than wt-ATTR (Table 4). Overall, survival
from enrollment in THAOS did not differ between
subjects with wt-ATTR and Val122Ile (Figure 3A).
Heart transplantation was performed more frequently
in Val122Ile subjects compared with subjects with
wild-type disease, which resulted in shorter time to
the combined outcome of death or cardiac trans-
plantation in Val122Ile compared with wt-ATTR sub-
jects (Figure 3B). In univariate analysis among
subjects with V122I and wt-ATTR, the following pa-
rameters were associated with reduced survival: age,
heart rate, estimated glomerular filtration rate, LV
mass index, SV, MCF, low-voltage QRS, and mean
arterial pressure but not mutation status (Table 5). In
multivariate analysis, the only independent pre-
dictors of survival were increased age and lower
mean arterial pressure.DISCUSSION
Principally, the present report found significant
regional differences in the demographic characteris-
tics, distinct mutations, and clinical manifestations of
subjects in THAOS in the United States compared
with the ROW (Central Illustration), including
different diagnostic approaches and differing use of
organ transplantation. Specifically, in the United
States, a majority of the subjects in the registry are
older men with a cardiac phenotype, with 72% of
enrolled subjects having either wt-ATTR or the
Val122Ile mutation, which differs from the most
common mutations reported from a large single-
center experience reported by the Mayo Clinic (17).
Accordingly, given that the majority of TTR amyloid
in THAOS in the United States is ATTR cardiomyop-
athy, it follows that there was a reliance on endo-
myocardial biopsy for establishing the diagnosis,
especially in light of the low sensitivity of fat pad
aspirate in ATTR (18). In addition, in areas in which
TABLE 4 Electrocardiography, Echocardiography, and Biomarkers: wt-ATTR Versus





p Valuen* Values n* Values
Electrocardiogram†
Atrial fibrillation/atrial flutter 78 62.8 27 51.9 0.3160
Conduction abnormalities 117 73.5 53 73.6 0.9912
Pacemaker‡ 111 28.8 46 8.7 0.0063
Low voltage 101 31.7 48 45.8 0.0931
LV hypertrophy 15 20 12 25 0.7562
Echocardiogram§
LVIDd, mm 94 44  6 45 42  7 0.0331
LVIDs, mm 85 34  7 38 32  7 0.1771
IVS thickness, mm 88 18  3 37 17  4 0.6980
PWT, mm 92 16  3 43 17  4 0.2786
Left atrial size, mm 74 50  10 33 46  6 0.0258
LV end-diastolic volume, ml 94 90  27 45 80  25 0.0457
LV end-systolic volume, ml 85 45  19 38 40  18 0.2334
Stroke volume, ml 85 45  16 38 40  14 0.0861
LV ejection fraction, % 85 51  12 38 51  11 0.9461
LV mass index, g/m2 88 165  44 41 158  46 0.4064
Myocardial contraction
fraction, %
85 15  7 35 16  11 0.9950
PA systolic pressure, mm Hg 48 39  12 8 43  17 0.5218
Biomakers
BNP, pg/ml 46 448 (323–645) 30 782 (454–1,407) 0.0007
NT-proBNP, pg/ml 57 3,123 (1,990–7,589) 20 2,734 (2,307–4,467) 0.4727
Troponin T, ng/ml 39 0.05 (0.02–0.07) 9 0.07 (0.03–0.14) 0.1209
Troponin I, ng/ml 43 0.09 (0.05–0.12) 22 0.11 (0.08–0.20) 0.1577
Values are %, mean  SD, or median (25th to 75th percentile). *Number of subjects with available data. †For
electrocardiogram and pacemaker parameters, n represents the number of patients with positive results of the
overall number of evaluations. ‡Artificial pacemaker with normal function. §For echocardiogram parameters, n
represents the overall number of evaluations.
BNP ¼ B-type natriuretic peptide; IVS ¼ interventricular septum; LV ¼ left ventricular; LVIDd ¼ left ventricular
internal dimension in diastole; LVIDs ¼ left ventricular internal dimension in systole; NT-proBNP ¼ N-terminal
pro–B-type natriuretic peptide; PA ¼ pulmonary artery; PWT ¼ posterior wall thickness; other abbreviations as in
Tables 1 and 2.
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168Val30Met mutation clusters (e.g., Portugal and
Brazil), a high pretest suspicion may reflect a praxis of
not searching for histopathologic proof, contributing
to a greater use of salivary gland biopsy specimens
and less of a reliance on biopsy overall.
ATTR cardiac amyloidosis is an underappreciated
and often underdiagnosed cause of heart failure in
the setting of a preserved ejection fraction (HFpEF)
(19) with TTR deposits seen in up to 30% of older
adults with HFpEF who undergo autopsy (20).
Because many of the manifestations of TTR-CM are
common with advancing age (e.g., heart failure, atrial
arrhythmias, conduction disturbances) and not
specific for this condition, heightened suspicion is
paramount to facilitate early diagnosis. Unfortu-
nately, the condition is often not entertained initially
and is only diagnosed in later phases of disease
(21) when there is significant myocardial amyloiddeposition and advanced restrictive cardiomyopathy.
In addition, although electrocardiographic evidence
of low voltage raises the suspicion of amyloid depo-
sition, the prevalence of low-voltage QRS in cardiac
amyloid depends on how low voltage is defined.
Standard definitions have low sensitivity, and
emerging evidence indicates that low voltage is a
relatively late finding in cardiac amyloidosis and may
not be useful for early identification (22). Amyloid-
osis, at present, remains a pathologic diagnosis and,
as shown by these data, various tissues are often
obtained to confirm the diagnosis. Unfortunately, the
most accessible tissue (fat pad) has an unacceptably
low sensitivity for establishing this potentially fatal
diagnosis (23,24), and endomyocardial biopsy, the
gold standard for diagnosis, is not widely available
and requires specialized expertise and techniques for
adequate interpretation. With the emergence of
potentially disease-modifying therapies, including
TTR stabilizers (25,26) and TTR silencers (27,28), the
need for early diagnosis is clear given that these
therapies are designed to reduce further deposition
but not address the effect of already deposited
amyloid.
Noninvasive radiotracer methods for establishing
the diagnosis of cardiac amyloidosis were initially
promoted by investigators in Europe (29–32) and have
been duplicated with bone isotopes available in the
United States (33). Whether such techniques can be
used for early identification of subjects with TTR-CM
is unknown, although several preliminary publica-
tions provide encouraging data suggesting that this
approach is worthy of future study (34,35). Indeed,
the reasons for the differences observed in the THAOS
registry between the United States and ROW (espe-
cially the frequency of wt-ATTR cardiac amyloid) are
unknown. They might reflect the true differences in
the prevalence of the condition but are more likely
related to an age difference in the population evalu-
ated, differences in the penetrance of scintigraphy
imaging techniques into clinical practice, differences
in reliance or expertise in the performance and
interpretation of endomyocardial biopsy specimens,
and/or patient preference.
Since its initial description (36) and subsequent
reports (37) highlighting the prevalence of the
Val122Ile mutation among individuals of African-
American descent, ATTR-CM secondary to this mu-
tation is believed to be the most common type of
ATTR amyloidosis worldwide. In THAOS, the
Val122Ile mutation is the second most common mu-
tation delineated after the Val30Met mutation. We do
not know whether this finding reflects true worldwide
disease prevalence or an underdiagnosed condition.
FIGURE 3 Time-to-Event Analysis in U.S. Subjects
Cumulative Mortality Estimate
Wild-type  (n = 123)
Val122Ile  (n = 66)
24 month estimate ± SE
Wild-type = 33.5% ± 6.5%
Val122Ile = 41.8% ± 7.7%
Log-rank P value = 0.2041
Cumulative Incidence Estimate
Wild-type  (n = 119)
Val122Ile  (n = 60)
24 month estimate ± SE
Wild-type = 36.0% ± 6.8%
Val122Ile = 57.2% ± 7.9%
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(A) Time to death did not differ between U.S. subjects with wild-type transthyretin amyloidosis
(ATTR) or valine-to-isoleucine substitution at position 122 (Val122Ile), but significantly more
Val122Ile patients underwent orthotopic heart transplantation, significantly reducing time to
death and transplantation (B) comparedwith patientswithwild-type transthyretin amyloidosis.
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169Although great expectations regarding the clinical
benefits of human genome have been anticipated,
genetic testing for monogenic disorders such as ATTR
amyloidosis is not widely used in the United States.
Data from THAOS supported this construct, in that
asymptomatic carriers of mutations in the TTR gene
that causes amyloidosis were more commonly re-
ported outside of the United States in endemic areas
such as Portugal, Japan, and other countries. As re-
ported in THAOS, the percentage who are asymp-
tomatic carriers in these countries are 35.6%, 9.8%,
and 20.4%, respectively, compared with 4.1% in the
United States. In addition, differences in use of clin-
ical genetic testing between minorities and non-
minorities might help explain these findings. This
approach is particularly relevant to the Val122Ile
mutation, which is prevalent in 3% to 4% of African-
American subjects at birth (38). A recent long-term
population-based study of Val122Ile carriers re-
ported clinically penetrant disease in approximately
20% (39), suggesting an estimated 25,000 affected
individuals in the United States.
Although the presence of a mutation could confer a
more severe phenotype or worse outcomes, data from
THAOS comparing the 2 most common forms of TTR
amyloid in the United States (wild-type and Val122Ile)
did not support a significant difference in outcomes.
There were clear racial differences in the population
affected, and subjects with Val122Ile presented at an
earlier age than wild-type patients; however, survival
from enrollment in THAOS did not differ. Except for
carpal tunnel syndrome, involvement of the periph-
eral nervous system in wt-ATTR has scarcely been
reported. Interestingly, subjects with Val122Ile had
greater evidence of a neuropathic phenotype
with more pain, numbness, tingling, and walkingTABLE 5 Univariate and Multivariate Analysis of Predictors of Survival*
Univariate Multivariate
n Hazard Ratio (95% CI) p Value n Hazard Ratio (95% CI) p Value
Age, per 5 yrs 280 1.374 (1.128–1.674) 0.0016 233 1.397 (1.123–1.738) 0.0027
Female (vs. male) 280 1.043 (0.374–2.911) 0.9355
Val122Ile (vs. wt-ATTR) 280 1.417 (0.825–2.433) 0.2063
Ejection fraction, per U 123 0.980 (0.952–1.010) 0.1933
Heart rate, per beat/min 229 1.023 (1.000–1.046) 0.0511
Stroke volume, per ml 123 0.969 (0.941–0.998) 0.0334
Myocardial contraction fraction, per U 120 0.928 (0.870–0.990) 0.0244
LV mass index, per g/m2 129 1.004 (0.997–1.012) 0.2501
eGFR $54 ml/min (vs. reference <54 ml/min) 194 0.583 (0.324–1.047) 0.0708
Low voltage present (vs. absent) 149 1.856 (0.853–4.038) 0.1187
Mean arterial pressure, per mm Hg 233 0.938 (0.908–0.969) <0.0001 233 0.937 (0.907–0.969) 0.0002
*From registry enrollment in wt-ATTR and Val122Ile subjects in the United States.
CI ¼ confidence interval; eGFR ¼ estimated glomerular filtration rate; other abbreviations as in Tables 1, 2, and 4.
CENTRAL ILLUSTRATION ATTR Characteristics Worldwide
Maurer, M.S. et al. J Am Coll Cardiol. 2016;68(2):161–72.
As determined in the THAOS (Transthyretin Amyloid Outcome Survey) registry, characteristics of patients with transthyretin amyloidosis (ATTR) differed between
patients in the United States and the rest of the world. U.S. patients seemed to be older, more often male and of African descent, and more commonly carried the valine-
to-isoleucine substitution at position 122 (Val122Ile) mutation. wt ¼ wild-type.
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170disability, and worse QOL. These data suggest that
although the predominant phenotype of Val122Ile is
cardiac, neurologic involvement (only recently
appreciated [40]) is part of the spectrum of this
condition.
Emerging therapies, including ATTR stabilizers or
silencers, have a solid biologic basis for evaluation
in ATTR, offering hope for patients with TTR
amyloid. Such therapies offer alternatives to liver
transplantation, not commonly performed in the
United States compared with the ROW. Organtransplantation is limited as a means of managing
ATTR. Because the majority of patients with cardiac
amyloidosis are older adults, transplantation of any
organ is often not feasible or ethical given the
shortage of donor organs and the concomitant
comorbidities that commonly occur with advanced
age. In addition, the benefits of transplantation
may be counterbalanced by the requirement of
lifelong immunosuppression, surgical risk in
already hemodynamically compromised patients, and
high expense. The literature suggests that liver
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: ATTR is an
underrecognized and underdiagnosed cause of HFpEF. In the
United States, data from THAOS suggest that this disease is
overwhelmingly a disorder of older adult male subjects with a
cardiac-predominant phenotype. Val122Ile is the most common
TTR mutation in the United States. Neurologic phenotypic
expression differed between wild-type disease and Val122Ile, but
survival from the time after enrollment in THAOS did not.
COMPETENCY IN PATIENT CARE: Patients with HFpEF with
unexplained increased wall thickness may have ATTR. Such pa-
tients should undergo appropriate diagnostic evaluation and, if
ATTR cardiac amyloid is confirmed, should be considered for
ongoing clinical trials or referral to an amyloid treatment center.
TRANSLATIONAL OUTLOOK 1: Additional studies will
determine the prevalence of ATTR in older adults with various
cardiovascular conditions, including HFpEF and atrial fibrillation.
TRANSLATIONAL OUTLOOK 2: Current clinical management
of ATTR is focused on symptomatic management, but ongoing
Phase III clinical trials will determine if TTR stabilizers or TTR
silencers have clinical benefits.
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171transplantation in isolation in older adult patients
with cardiomyopathy is not effective, and combined
heart and liver transplantation is usually reserved for
younger individuals (41). In addition, amyloid pro-
gression might potentially progress after organ
transplant; normal wild-type TTR can build up on
previously deposited TTR in the heart and nerves,
leading to recurrent amyloid cardiomyopathy or
progression of polyneuropathy. Emerging treatments
might provide an alternative strategy and have
certainly contributed to the heightened awareness of
this progressive clinical condition.
STUDY LIMITATIONS. Although our study is the
largest report of patients with ATTR to date, some
limitations of these data should be noted. The large
number of subjects from Portugal, where the geno-
type is almost exclusively Val30Met, might have
influenced our results. However, many of the differ-
ences between the United States and the ROW per-
sisted after stratification for whether the site
principal investigator was or was not a cardiologist,
suggesting that even subjects with a cardiac pheno-
type differed in the United States from the ROW. In-
formation entered into the registry was obtained for
clinical purposes and not mandated by study proto-
col. As a result, given the different practice patterns
and availability of specific tests in particular parts of
the world, there were considerable missing data that
could have influenced some of the reported results.
Specifically, the absence of biomarker data (e.g.,
troponin, B-type natriuretic peptides) may have
influenced the outcome of the multivariate analysis.
The absence of a core laboratory or central review
of various tests such as echocardiograms could have
contributed to errors in data integrity. However,
specific guidelines for reporting the elements of in-
terest were provided to sites to minimize the chance
of data variability by site. Follow-up in THAOS is
ongoing, and a large percentage of subjects have not
had sufficient follow-up to be included in the survival
analysis. However, the subjects with follow-up did
not differ from those without follow-up regarding any
demographic, clinical, or echocardiographic features,
except for New York Heart Association functional
class, suggesting validity of our findings. After con-
trolling for age, additional survival analyses from
time of diagnosis did not reveal a significant differ-
ence in outcome between subjects with wild-typeand Val122Ile disease, also suggesting the validity of
the reported results. Finally, new imaging modalities
(e.g., speckle-tracking strain, magnetic resonance
imaging, scintigraphy) were not recorded in the
THAOS registry.
CONCLUSIONS
ATTR in the United States is overwhelmingly a dis-
order of older adult male subjects with a cardiac
phenotype, and Val122Ile is the most common muta-
tion. Neurologic phenotypic expression differed be-
tween wild-type disease and Val122Ile, but survival
from enrollment in THAOS did not.
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